Neurology-Neuroimmunology & Neuroinflammation

Papers
(The H4-Index of Neurology-Neuroimmunology & Neuroinflammation is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes374
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID120
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome109
Neurosarcoidosis106
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-1990
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis88
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France85
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis84
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders79
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-1974
COVID-19 Among Patients With Multiple Sclerosis72
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis68
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders68
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression61
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease60
Presentations and mechanisms of CNS disorders related to COVID-1957
IgG4-Mediated Neurologic Autoimmunities56
COVID-19 Severity in Multiple Sclerosis56
New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD54
Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF53
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis53
Retinal Optical Coherence Tomography in Neuromyelitis Optica53
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection49
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder47
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders46
Chitinases and chitinase-like proteins as biomarkers in neurologic disorders46
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab45
Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease45
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder45
Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis44
Anti-IgLON5 Disease44
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS43
Toward Precision Phenotyping of Multiple Sclerosis41
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis41
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders40
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection39
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies39
Seizure-related 6 homolog like 2 autoimmunity39
Gene-Environment Interactions in Multiple Sclerosis38
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children38
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes38
0.036940097808838